Switch theme
Sign up to access all valuation multiples
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).
2004
16.1K+
LTM Revenue $491M
LTM EBITDA $56.6M
$961M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akums has a last 12-month revenue (LTM) of $491M and a last 12-month EBITDA of $56.6M.
In the most recent fiscal year, Akums achieved revenue of $482M and an EBITDA of $62.5M.
Akums expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akums valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $491M | XXX | $482M | XXX | XXX | XXX |
| Gross Profit | $199M | XXX | $197M | XXX | XXX | XXX |
| Gross Margin | 41% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $56.6M | XXX | $62.5M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $39.0M | XXX | $36.0M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $38.4M | XXX | $40.3M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Akums's stock price is INR 571 (or $7).
Akums has current market cap of INR 87.4B (or $1.0B), and EV of INR 82.1B (or $961M).
See Akums trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $961M | $1.0B | XXX | XXX | XXX | XXX | $0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Akums has market cap of $1.0B and EV of $961M.
Akums's trades at 2.0x EV/Revenue multiple, and 19.0x EV/EBITDA.
Equity research analysts estimate Akums's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Akums has a P/E ratio of 26.7x.
See valuation multiples for Akums and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $961M | XXX | $961M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 17.0x | XXX | 19.0x | XXX | XXX | XXX |
| EV/EBIT | 24.7x | XXX | 25.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 26.7x | XXX | 33.9x | XXX | XXX | XXX |
| EV/FCF | 705.9x | XXX | 42.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAkums's last 12 month revenue growth is 11%
Akums's revenue per employee in the last FY averaged $30K, while opex per employee averaged $10K for the same period.
Akums's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Akums's rule of X is 39% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Akums and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | 26% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $30K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $10K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akums acquired XXX companies to date.
Last acquisition by Akums was XXXXXXXX, XXXXX XXXXX XXXXXX . Akums acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Akums founded? | Akums was founded in 2004. |
| Where is Akums headquartered? | Akums is headquartered in India. |
| How many employees does Akums have? | As of today, Akums has 16.1K+ employees. |
| Is Akums publicy listed? | Yes, Akums is a public company listed on BOM. |
| What is the stock symbol of Akums? | Akums trades under 544222 ticker. |
| When did Akums go public? | Akums went public in 2024. |
| Who are competitors of Akums? | Similar companies to Akums include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Akums? | Akums's current market cap is $1.0B |
| What is the current revenue of Akums? | Akums's last 12 months revenue is $491M. |
| What is the current revenue growth of Akums? | Akums revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Akums? | Current revenue multiple of Akums is 2.0x. |
| Is Akums profitable? | Yes, Akums is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Akums? | Akums's last 12 months EBITDA is $56.6M. |
| What is Akums's EBITDA margin? | Akums's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Akums? | Current EBITDA multiple of Akums is 17.0x. |
| What is the current FCF of Akums? | Akums's last 12 months FCF is $1.4M. |
| What is Akums's FCF margin? | Akums's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Akums? | Current FCF multiple of Akums is 705.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
